Pramipexole, the active ingredient in the Parkinson’s disease therapy Mirapex, appears to overactivate a brain region known as the external globus pallidus — findings that could explain the poor decision-making and impulse control that occurs
Subcutaneous, or under-the-skin, injections of COYA 302, a combination therapy in development by Coya Therapeutics, were found to reduce excessive inflammation and immune cell activation in a mouse model of Parkinson’s disease. These beneficial effects
Electroacupuncture reduced cellular hallmarks of Parkinson’s disease, including alpha-synuclein accumulation and nerve cell degeneration, in a mouse model of the disease. That’s according to the findings from a study that also found the treatment, a